Jyong Biotech Appoints Wei Zhang as New CFO, Citing IPO and Fundraising Expertise

summarizeSummary

Jyong Biotech Ltd. announced the appointment of Wei (Vivi) Zhang as its new Chief Financial Officer, effective immediately. Ms. Zhang brings extensive experience in initial public offerings, fundraising, and public company finance.

check_boxKey Events

• New Chief Financial Officer Appointed

  Wei (Vivi) Zhang has been appointed as the Company's Chief Financial Officer, effective February 6, 2026.

• Replaces Previous CFO

  Ms. Zhang will be replacing Alfred Ying in the CFO role.

• Extensive Financial Leadership Experience

  Ms. Zhang brings significant experience in initial public offerings, fundraising, and public company financial management, including a prior CFO position at a Nasdaq-listed company (Global Mofy AI Limited).

auto_awesomeAnalysis

The appointment of Wei (Vivi) Zhang as Chief Financial Officer is a notable executive change for Jyong Biotech. Ms. Zhang's extensive background in initial public offerings, fundraising, and managing finances for public companies, including a previous CFO role at a Nasdaq-listed entity, suggests a strategic move to bolster the company's financial leadership. This expertise could be particularly valuable as the company navigates future capital market activities and growth initiatives, especially following its recent significant capital injection.